628例难以控制的高血压临床分析
|
摘要
目的了解住院的难以控制的高血压患者病因分布、合并的代谢紊乱及其靶器官损害的状况;并观察代谢紊乱、靶器官损害在原发性高血压和继发性高血压中分布的差异。方法回顾性分析了1997～2005年间在高血压专科住院的628例难以控制的高血压患者的病历资料,观察其病因分布、合并的代谢紊乱及其靶器官损害的状况;并观察代谢紊乱和靶器官损害在原发性高血压和继发性高血压中分布的差异。采用SPSS13.0软件行统计学分析。结果1.在628例难以控制的高血压患者中原发性高血压占80.10%,继发性高血压占18.95%,病因待定者占0.95%。2.在119例难以控制的继发性高血压患者中,肾血管性高血压所占比例最高(33.61%),接下来为睡眠呼吸暂停综合征(23.53%),肾实质性高血压(15.97%),原发性醛固酮增多症(13.45%)。3.在628例难以控制的高血压患者中,合并脂代谢紊乱占66.24%,合并糖代谢紊乱占43.78%;与继发性高血压比较,在难以控制的原发性高血压中糖尿病的患病率(P<0.001)和体重指数的水平(P<0.05)更高。4.在628例难以控制的高血压患者中,合并脑卒中、冠心病、慢性心功能不全、慢性肾功能不全分别为39.97%、31.85%、16.57%、29.62%;与继发性高血压比较,在难以控制的原发性高血压中合并脑卒中(P<0.05)、冠心病(P<0.001)的比例较高;慢性肾功能不全(P<0.001)多见于难以控制的继发性高血压患者。5.与原发性高血压比较,难以控制的继发性高血压患者的年龄较轻,血压水平更高。结论难以控制的住院高血压患者中原发性高血压占多数,肾性高血压、睡眠呼吸暂停综合征是继发性高血压中血压难以控制的主要原因;难以控制的高血压患者多合并糖脂代谢紊乱,心、脑、肾靶器官损害严重,有效的控制血压并纠正代谢紊乱对降低靶器官损害有重要的意义。
Objective To analyze the etiology, metabolic disorders and target organ damage of in-patients hypertensives whose blood pressure were difficult to control and to observe differences of metabolic disorders and target organ damage between essential hypertension(EH) and secondary hypertension(SH) in order to provide basis of correct diagnosis and therapy of these hyperensives. Methods Retrospective study was performed based on etiology, metabolic disorders and target organ damage of 628 in-patients hypertensives whose blood pressure were difficult to control in department of hypertension, People's Hospital of Xinjiang Uighur Autonomous Region, from September 1997 to December 2005. Comparison of metabolic disorders and target organ damage between EH and SH were performed. The datum were analyzed by using SPSS 13.0 software package. Results 1.Of 628 in-patients hypertensives whose blood pressure were difficult to control, there were 80.10% of EH, 18.95% of SH and 0.95% of indefinite diagnosis. 2.119 SH comprised 33.61% of renovascular hypertension, 15.97% of renal hypertension , 23.53 % of obstructive sleep apnea syndrome, 13.45% of primary aldosteronism, 5.04% of pheochromocytoma. 3. Of 628 in-patients hypertensives whose blood pressure were difficult to control, there were 66.24% of dyslipidemia, 43.78% of abnormality of glucose metabolism. Prevalence of diabetes mellitus (P<0.001)and level of body mass index(P<0.05) in essential hypertension were higher than those in secondary hypertension. 4. Of 628 in-patients hypertensives whose blood pressure were difficult to control, prevalence of stroke, coronary heart disease, chronic heart failure, chronic renal inadequacy were 39.97%, 31.85%, 16.57%, 29.62%, respectively. Prevalence of stroke, coronary heart disease and age in EH were higher than those in SH. Prevalence of chronic renal inadequacy and levels of blood pressure in SH were higher than those in EH. Conclusion EH was main composition in in-patients hypertensives whose blood pressure were difficult to control, renal and renovascular hypertension and obstructive sleep apnea syndrome were major cause of blood pressure difficult to control. Most hypertensives whose blood pressure was difficult to control complicated with metabolic disorders, there were severe target organ damage in those hypertensives. It play an important role on protection of target organ damage to make blood pressure control and rectify metabolic disorders.
Objective To analyze the etiology, metabolic disorders and target organ damage of in-patients hypertensives whose blood pressure were difficult to control and to observe differences of metabolic disorders and target organ damage between essential hypertension(EH) and secondary hypertension(SH) in order to provide basis of correct diagnosis and therapy of these hyperensives. Methods Retrospective study was performed based on etiology, metabolic disorders and target organ damage of 628 in-patients hypertensives whose blood pressure were difficult to control in department of hypertension, People's Hospital of Xinjiang Uighur Autonomous Region, from September 1997 to December 2005. Comparison of metabolic disorders and target organ damage between EH and SH were performed. The datum were analyzed by using SPSS 13.0 software package. Results 1.Of 628 in-patients hypertensives whose blood pressure were difficult to control, there were 80.10% of EH, 18.95% of SH and 0.95% of indefinite diagnosis. 2.119 SH comprised 33.61% of renovascular hypertension, 15.97% of renal hypertension , 23.53 % of obstructive sleep apnea syndrome, 13.45% of primary aldosteronism, 5.04% of pheochromocytoma. 3. Of 628 in-patients hypertensives whose blood pressure were difficult to control, there were 66.24% of dyslipidemia, 43.78% of abnormality of glucose metabolism. Prevalence of diabetes mellitus (P<0.001)and level of body mass index(P<0.05) in essential hypertension were higher than those in secondary hypertension. 4. Of 628 in-patients hypertensives whose blood pressure were difficult to control, prevalence of stroke, coronary heart disease, chronic heart failure, chronic renal inadequacy were 39.97%, 31.85%, 16.57%, 29.62%, respectively. Prevalence of stroke, coronary heart disease and age in EH were higher than those in SH. Prevalence of chronic renal inadequacy and levels of blood pressure in SH were higher than those in EH. Conclusion EH was main composition in in-patients hypertensives whose blood pressure were difficult to control, renal and renovascular hypertension and obstructive sleep apnea syndrome were major cause of blood pressure difficult to control. Most hypertensives whose blood pressure was difficult to control complicated with metabolic disorders, there were severe target organ damage in those hypertensives. It play an important role on protection of target organ damage to make blood pressure control and rectify metabolic disorders.
引文
[1] Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide[J]. Hypertension.2004, 44(5):398–404.
[2] Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000[J]. JAMA. 2003,290: 199–206.
[3]中国高血压防治指南修订委员会.中国高血压防治指南2005年修订版[M] .北京:人民卫生出版社,2005:12.
[4] Mancia G, de Backer D, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hypertens.2007,25 (6):1105-1187.
[5]李南方,王磊,周克明,等.新疆自治区人民医院高血压患者病因构成特点.中华心血管病杂志[J].2007,35(9):865-868.
[6]袁和顺.高血压与相关疾病的调查分析[J].实用预防医学. 2002,5(3):547
[7]陈国伟.高血压与糖尿病[J].中国实用内科杂志.2002,4(8):1999
[8] Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension[J]. Hypertens, 1997; 17(12):869-872
[9]高鑫,江孙芳,赵耐青,等.超重及肥胖高血压患者空腹胰岛素、胰岛素原、瘦素水平与高血压的关系[J].复旦学报(医学科学版).2001,28 (4): 320-321.
[10]徐兴森,杨万涛,刘道燕,等.高血压合并代谢紊乱及对心肾血管的影响[J].中华高血压杂志.2006: 14 (11): 894-898.
[11] Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis [J]. JAMA. 2003; 289: 2534–2544.
[12] Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J]. Hypertension. 2003,42:1206–1252.
[13] Wong ND, Thakral G, Franklin SS, et al. Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex [J]. Am Heart J. 2003,145:888–895.
[14] Ho PM, Masoudi FA, Peterson ED, et al. Cardiology management improves secondary prevention measures among patients with coronary artery disease[J]. J AmColl Cardiol. 2004;43:1517–1523.
[15]王志华,初少莉,陈绍行,等,.高血压住院患者病因及危险因素分析[J].高血压杂志.2005,13(8):405-409.
[16] Norman M., kaplan. KAPLAN[M].临床高血压:第8版:山东科技出版社, 2004,15-23;333-452;469-473.
[17]叶任高,陆在英.内科学[M].第6版:人民卫生出版社, 2004,272-302,542-551.
[18]血脂异常防治对策专题组.血脂异常防治建议[J].中华心血管病杂志.1997 ,25 :169-172.
[19] In KC, Lin HY, Chou P. Community based epidemiologic study on
[20] hyperuricemiaand gout in Kin-Hu , Kinmen [J]. J heumatol.2000, 27 :1045-
[21] 1050.
[22] Setaro JF, Black HR. Refractory hypertension[J]. N Engl J Med ,1992 ,327 :
[23] 543～547.
[24]陈惠,朱鹏立,吴小盈.难治性高血压[M].福建科学技术出版社.2005,50.
[25]张晓英.老年人肾性高血压的治疗[J].中华老年医学杂.2006,25(2):154-156.
[26]曾正陪.内分泌性高血压的现状及诊治[J].临床内科杂志.2006,23(3):149.
[27]张远慧.肾血管性高血压[J].新医学.2006,37(5):287-289.
[28]刘润梅.肾实质性高血压[J].人民军医.2003,46 (2): 92-93.
[29] Lologan AG, Perilikowski SM,Mente A,et al. High prevalance of unrecognized sleep apnea in drug resistant hygpertension [J].J Hypertens. 2001 ,19 (12) :2271 - 2277.
[30] Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep disordered breathing and hypertension[J] . N Engl J Med.2000 , 342(5): 1378-1384.
[31] Cutler M J, Swift N M, Keller D M, et al. Periods of Intermittent Hypoxic Apnea can Alter Chemoreflex Control of Sympa-thetic Nerve Activity in Humans[J]. Am J Physiol Heart Circ Physiol. 2004, 287 (5): 2054-2060.
[32] Jordan W, Reinbacher A, Cohrs S, et al. Obst ructive Sleep Apnea: Plasma Endot helin21 Precursor but not Endot helin21 Levels are Elevated and Decline with Nasal Continuous Positive AirwayPressure[J].Peptides.2005,26(9):1654
[33] -1660.
[34]徐劲松,黄国明,夏国际,等.中重度睡眠呼吸暂停综合征合并高血压的临床特点探讨[J].实用临床学.2007,8(8):29-31.
[35] Zhong X, Xiao Y, Robert C, et al. Effects of Antihypertensives on Arterial Responses Associated wit h Obstructive Sleep Apneas[J]. Chinese Medical Journal. 2005 ,118(2) :123-129.
[36]严江涛,汪道文.原发性醛固酮增多症的诊疗进展[J].临床内科杂志.2005, 22 (7) : 433.
[37] Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension [J]. Hypertension.2002, 40 (6): 892 - 896.
[38] Keh-Chuan Loh, Evelyn S, Koay, et al. Prevalence of Primary Aldosteronism among Asian Hypertensive Patients in Singapore[J].The Journal of Clinical Endocrinology & Metabolism. 2000,85(8): 2854-2859.
[39]喻晶,申怡,张木勋,等.原发性醛固酮增多症67例临床分析[J].中国实用内科杂志.2006, 26(22):1825.
[40] Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best?[J].JAMA.2002,287:1427-1434.
[41] Williams RR , Hunt SC , Hopkins PN , et al. Familial dyslipidemic
[42] hypertension:Evidence from 58 Utah families for a syndrome present in approximately 12 % of patients with essential hypertension[J].JAMA .1988 ,
[43] 259 (24) :3579– 3586.
[44]王景福,张新梅,陈电波,等.1080例高血压病与超重、血脂异常、糖耐量降低及糖尿病发病关系分析[J].心血管康复医学杂志.2000,9(4):23-25.
[45]陆俊茜,贾伟平,包玉倩,等.上海社区高血压人群伴发糖代谢异常的现状及特点[J].上海医学. 2006,29(9):603-606.
[46]严冬,王招娣,肖党生,等. 721例高血压相关危险因素分析[J].浙江预防医学.2006 , 18, (9):14-15.
[47]邱朝晖,曹奕.高尿酸血症与高血压的关系[J].国外医学心血管疾病分册.2001 ,28(1) :9～11.
[48]沈琪琳,周位强,邢志广.高血压患者降压治疗前后血尿酸水平的变化[J].中国慢性病预防与控制. 2007,15(4):367-372.
[49]梁丹.2型糖尿病合并高血压的血尿酸结果分析[J].广西医学.2006,28(9): 14023-1403.
[50]詹思延,高原原,尹香君,等.同型半胱氨酸代谢异常与原发性高血压的病例对照研究[J].中华流行病学杂志. 2000, 21 (3) : 194-197.
[51] Van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure[J]. Curr Hypertens Rep. 2003, 5 (1) : 26-31.
[52]孙晓楠,李玉明,郭红.单纯收缩期高血压患者同型半胱氨酸代谢关键酶基因多态性相关因子研究[J].中华心血管病杂志, 2003,31 (4) : 272.
[53] Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988–1994[J]. Am J Prev Med. 2002:22(1):42–48.
[54] Kissela BM, Khoury J, Kleindorfer D,et al. Epidemiology of ischemic stroke in patients with diabetes: the Greater Cincinnati/Northern Kentucky Stroke Study[J]. Diabetes Care. 2005,28(7): 355–359,
[55] Pausova Z, DeslauriersB, Gaudet D, et al. Role of tumor necrosis factorαgenelocus in obesity and obesity associated hypertension in French Canadians [J]. Hypertension,.2000, 36: 14-19.
[56]程莹,潘长玉.体重指数在老年代谢综合征人群中诊断价值的初步探讨[J].中华内科杂志.2006,45(2):100-103.
[57] David Curb, Robert D. Abbott, Charles J. MacLean, et al. Age-related changes in stroke risk in men with hypertension and normal blood pressure[J]. Stroke.1996, 27(6): 819-824.
[58] Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews[J]. Stroke. 2004, 35(6): 776 -785
[59] Lisheng L. Effects of hypertension control in older Chinese patients with isolated systolic hypetension: a progress report on the Syst-China[J]. J hum Hypertens.1996:10 (Suppl 1): S9-11.
[60]王瑛,邓翠云,王珍霞,等.长春市公务员原发性高血压流行病学研究[J].心血管康复医学杂志. 2004, 13(1): 19-20.
[61]钱岳晨、朱鼎良、李勇,等.上海地区门诊高血压人群降压治疗现状[J].上海医学.2007, 30(增):1.
[62]关绍晨,汤哲,李静,等.老年人血压水平与冠心病和脑卒中发病关系的研究[J].中华老年心脑血管病志. 2007, 9(3):166-169.
[63]耿延君.高血压与心脑血管疾病研究[J].中国社区医师.2007,6(13):5-6.
[64] Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and rends on obesity among US adults, 1999-2000 [J]. JAMA. 2002,288(14):1723- 1727
[65]谌贻璞.肾实质性高血压的治疗进展[J].中华心血管病杂志,2003, 31 (7):554.
[1] Chobanian AV, Bakris GL,Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [J]. JAMA. 2003,289 (19): 2560-2572.
[2] Mancia G, de Backer D, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hypertens.2007, 25 (6):1105-1187.
[3]张维忠.顽固性高血压的评估与处理[J].内科急危重症杂志. 2004,10 (2):60-61.
[4] Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac organ damage in refractory hypertension [J]. J ypertension.2001, 19(10):2063-2070.
[5] Veglio F, Rabbia F, Riva P, et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension[J]. Clin Exp Hypertension. 2001, 23(5): 203 - 211.
[6] Staessen JA, Hond ED, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician’s office: A randomized controlled trial[J]. JAMA.2004,291(7):955-964.
[7]施仲伟.顽固性高血压的降压药物治疗[J].心血管病学进展.2007,28(5): 665.
[8]美国卫生研究院,美国心肺血研究院.美国高血压教育计划,美国联邦委员会关于高血压预防、检测、评定及治疗第六次报告[J].心血管病学进展.1998,19(4):242-244.
[9] Burnier M, Schneider MP , Chioléro A , et al. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions[J].J Hypertension.2001,19(6):335-341.
[10]沈洪兵,钮菊英,姚才良,等.饮茶与血压关系的流行病学调查[J].高血压杂志.1999,4(2): 156.
[11] Sleight P. Smoking and hypertension[J] . Clin Exp Hypertens. 1983 ,24(2):233.
[12] O’Rorke JE, Richardson W S. What to do when blood pressure is difficult to control[J]. Br Med J. 2001, 322 (7296): 1229-1232.
[13] Garg J P, Elliott WJ ,Folker A, et al. Resistant hypertension revisited: A comparison of two university-based cohorts[J]. Am J Hypertension. 2005,18(6):619-626.
[14] Whelton A, Fort J G, Puma JA, et al. Cyclooxygenase - 2$ specific inhibitors andcardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients[J]. Am J Ther. 2001,8:85-95.
[15] Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic[J]. Arch Intern Med. 1991,15(6): 1786-1792.
[16]纪宝华.顽固性高血压治疗对策[J].中华心血管病杂志,2003,31(5):396.
[17] Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts[J].Am J Hypertens. 2005,18(5,pt1):619-626.
[18]纪宝华.顽固性高血压应警惕原发性醛固酮增多症[J].高血压杂志.2002,10(4):306.
[19] Calhoun DA, N ishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subject swith resistant hypertension[J]. Hypertension. 2002, 40(6):892-896.
[20] Shopard JP. Cardiorespiratory changes on obstructive sleep apnea. In:Kergger. Roth, Dement: principles and practice of sleep medicinend [J].Philadelphia.
[21] 1994,86(5): 657-666.
[22]李岩.继发性高血压的诊断[J]..实用乡村医生杂志.2003,10(6):34-36.
[23] Park J, Campese V. Clinical characteristics of resistant hypertension: the importance of comp liance and the role of diagnostic evaluation in delineating pathogenesis[J]. J Clin Hypertens. 2007, 9 (supp l 1) : 7212.
[24] MoserM, Setaro JF. Resistant or difficult to control hypertension [J]. N Engl J Med. 2006, 355(4): 385-392.
[25] Hirsch S. A different approach to resistant hypertension [J]. Cleveland Clin J Med.
[26] 2007, 74(6): 449-456.
[27] Nishzaka MK, Zaman MA, Calhoun DA. Efficacy of low-dosesp ironolactone in subjectswith resistant hypertension[J]. Am J Hypertens. 2003, 16 (11, pt1):925-930.
[28] Zannad F. Aldosterone antagonist in resistant hypertension [J]. J Hypertens. 2007, 25(4):747-750.
[29] Epstein M. Resistant hypertension: prevalence and evolving concepts [J]. J Clin Hypertens. 2007, 9 (supp l 1):226.
[2] Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000[J]. JAMA. 2003,290: 199–206.
[3]中国高血压防治指南修订委员会.中国高血压防治指南2005年修订版[M] .北京:人民卫生出版社,2005:12.
[4] Mancia G, de Backer D, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hypertens.2007,25 (6):1105-1187.
[5]李南方,王磊,周克明,等.新疆自治区人民医院高血压患者病因构成特点.中华心血管病杂志[J].2007,35(9):865-868.
[6]袁和顺.高血压与相关疾病的调查分析[J].实用预防医学. 2002,5(3):547
[7]陈国伟.高血压与糖尿病[J].中国实用内科杂志.2002,4(8):1999
[8] Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension[J]. Hypertens, 1997; 17(12):869-872
[9]高鑫,江孙芳,赵耐青,等.超重及肥胖高血压患者空腹胰岛素、胰岛素原、瘦素水平与高血压的关系[J].复旦学报(医学科学版).2001,28 (4): 320-321.
[10]徐兴森,杨万涛,刘道燕,等.高血压合并代谢紊乱及对心肾血管的影响[J].中华高血压杂志.2006: 14 (11): 894-898.
[11] Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis [J]. JAMA. 2003; 289: 2534–2544.
[12] Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J]. Hypertension. 2003,42:1206–1252.
[13] Wong ND, Thakral G, Franklin SS, et al. Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex [J]. Am Heart J. 2003,145:888–895.
[14] Ho PM, Masoudi FA, Peterson ED, et al. Cardiology management improves secondary prevention measures among patients with coronary artery disease[J]. J AmColl Cardiol. 2004;43:1517–1523.
[15]王志华,初少莉,陈绍行,等,.高血压住院患者病因及危险因素分析[J].高血压杂志.2005,13(8):405-409.
[16] Norman M., kaplan. KAPLAN[M].临床高血压:第8版:山东科技出版社, 2004,15-23;333-452;469-473.
[17]叶任高,陆在英.内科学[M].第6版:人民卫生出版社, 2004,272-302,542-551.
[18]血脂异常防治对策专题组.血脂异常防治建议[J].中华心血管病杂志.1997 ,25 :169-172.
[19] In KC, Lin HY, Chou P. Community based epidemiologic study on
[20] hyperuricemiaand gout in Kin-Hu , Kinmen [J]. J heumatol.2000, 27 :1045-
[21] 1050.
[22] Setaro JF, Black HR. Refractory hypertension[J]. N Engl J Med ,1992 ,327 :
[23] 543～547.
[24]陈惠,朱鹏立,吴小盈.难治性高血压[M].福建科学技术出版社.2005,50.
[25]张晓英.老年人肾性高血压的治疗[J].中华老年医学杂.2006,25(2):154-156.
[26]曾正陪.内分泌性高血压的现状及诊治[J].临床内科杂志.2006,23(3):149.
[27]张远慧.肾血管性高血压[J].新医学.2006,37(5):287-289.
[28]刘润梅.肾实质性高血压[J].人民军医.2003,46 (2): 92-93.
[29] Lologan AG, Perilikowski SM,Mente A,et al. High prevalance of unrecognized sleep apnea in drug resistant hygpertension [J].J Hypertens. 2001 ,19 (12) :2271 - 2277.
[30] Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep disordered breathing and hypertension[J] . N Engl J Med.2000 , 342(5): 1378-1384.
[31] Cutler M J, Swift N M, Keller D M, et al. Periods of Intermittent Hypoxic Apnea can Alter Chemoreflex Control of Sympa-thetic Nerve Activity in Humans[J]. Am J Physiol Heart Circ Physiol. 2004, 287 (5): 2054-2060.
[32] Jordan W, Reinbacher A, Cohrs S, et al. Obst ructive Sleep Apnea: Plasma Endot helin21 Precursor but not Endot helin21 Levels are Elevated and Decline with Nasal Continuous Positive AirwayPressure[J].Peptides.2005,26(9):1654
[33] -1660.
[34]徐劲松,黄国明,夏国际,等.中重度睡眠呼吸暂停综合征合并高血压的临床特点探讨[J].实用临床学.2007,8(8):29-31.
[35] Zhong X, Xiao Y, Robert C, et al. Effects of Antihypertensives on Arterial Responses Associated wit h Obstructive Sleep Apneas[J]. Chinese Medical Journal. 2005 ,118(2) :123-129.
[36]严江涛,汪道文.原发性醛固酮增多症的诊疗进展[J].临床内科杂志.2005, 22 (7) : 433.
[37] Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension [J]. Hypertension.2002, 40 (6): 892 - 896.
[38] Keh-Chuan Loh, Evelyn S, Koay, et al. Prevalence of Primary Aldosteronism among Asian Hypertensive Patients in Singapore[J].The Journal of Clinical Endocrinology & Metabolism. 2000,85(8): 2854-2859.
[39]喻晶,申怡,张木勋,等.原发性醛固酮增多症67例临床分析[J].中国实用内科杂志.2006, 26(22):1825.
[40] Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best?[J].JAMA.2002,287:1427-1434.
[41] Williams RR , Hunt SC , Hopkins PN , et al. Familial dyslipidemic
[42] hypertension:Evidence from 58 Utah families for a syndrome present in approximately 12 % of patients with essential hypertension[J].JAMA .1988 ,
[43] 259 (24) :3579– 3586.
[44]王景福,张新梅,陈电波,等.1080例高血压病与超重、血脂异常、糖耐量降低及糖尿病发病关系分析[J].心血管康复医学杂志.2000,9(4):23-25.
[45]陆俊茜,贾伟平,包玉倩,等.上海社区高血压人群伴发糖代谢异常的现状及特点[J].上海医学. 2006,29(9):603-606.
[46]严冬,王招娣,肖党生,等. 721例高血压相关危险因素分析[J].浙江预防医学.2006 , 18, (9):14-15.
[47]邱朝晖,曹奕.高尿酸血症与高血压的关系[J].国外医学心血管疾病分册.2001 ,28(1) :9～11.
[48]沈琪琳,周位强,邢志广.高血压患者降压治疗前后血尿酸水平的变化[J].中国慢性病预防与控制. 2007,15(4):367-372.
[49]梁丹.2型糖尿病合并高血压的血尿酸结果分析[J].广西医学.2006,28(9): 14023-1403.
[50]詹思延,高原原,尹香君,等.同型半胱氨酸代谢异常与原发性高血压的病例对照研究[J].中华流行病学杂志. 2000, 21 (3) : 194-197.
[51] Van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure[J]. Curr Hypertens Rep. 2003, 5 (1) : 26-31.
[52]孙晓楠,李玉明,郭红.单纯收缩期高血压患者同型半胱氨酸代谢关键酶基因多态性相关因子研究[J].中华心血管病杂志, 2003,31 (4) : 272.
[53] Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988–1994[J]. Am J Prev Med. 2002:22(1):42–48.
[54] Kissela BM, Khoury J, Kleindorfer D,et al. Epidemiology of ischemic stroke in patients with diabetes: the Greater Cincinnati/Northern Kentucky Stroke Study[J]. Diabetes Care. 2005,28(7): 355–359,
[55] Pausova Z, DeslauriersB, Gaudet D, et al. Role of tumor necrosis factorαgenelocus in obesity and obesity associated hypertension in French Canadians [J]. Hypertension,.2000, 36: 14-19.
[56]程莹,潘长玉.体重指数在老年代谢综合征人群中诊断价值的初步探讨[J].中华内科杂志.2006,45(2):100-103.
[57] David Curb, Robert D. Abbott, Charles J. MacLean, et al. Age-related changes in stroke risk in men with hypertension and normal blood pressure[J]. Stroke.1996, 27(6): 819-824.
[58] Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews[J]. Stroke. 2004, 35(6): 776 -785
[59] Lisheng L. Effects of hypertension control in older Chinese patients with isolated systolic hypetension: a progress report on the Syst-China[J]. J hum Hypertens.1996:10 (Suppl 1): S9-11.
[60]王瑛,邓翠云,王珍霞,等.长春市公务员原发性高血压流行病学研究[J].心血管康复医学杂志. 2004, 13(1): 19-20.
[61]钱岳晨、朱鼎良、李勇,等.上海地区门诊高血压人群降压治疗现状[J].上海医学.2007, 30(增):1.
[62]关绍晨,汤哲,李静,等.老年人血压水平与冠心病和脑卒中发病关系的研究[J].中华老年心脑血管病志. 2007, 9(3):166-169.
[63]耿延君.高血压与心脑血管疾病研究[J].中国社区医师.2007,6(13):5-6.
[64] Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and rends on obesity among US adults, 1999-2000 [J]. JAMA. 2002,288(14):1723- 1727
[65]谌贻璞.肾实质性高血压的治疗进展[J].中华心血管病杂志,2003, 31 (7):554.
[1] Chobanian AV, Bakris GL,Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [J]. JAMA. 2003,289 (19): 2560-2572.
[2] Mancia G, de Backer D, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hypertens.2007, 25 (6):1105-1187.
[3]张维忠.顽固性高血压的评估与处理[J].内科急危重症杂志. 2004,10 (2):60-61.
[4] Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac organ damage in refractory hypertension [J]. J ypertension.2001, 19(10):2063-2070.
[5] Veglio F, Rabbia F, Riva P, et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension[J]. Clin Exp Hypertension. 2001, 23(5): 203 - 211.
[6] Staessen JA, Hond ED, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician’s office: A randomized controlled trial[J]. JAMA.2004,291(7):955-964.
[7]施仲伟.顽固性高血压的降压药物治疗[J].心血管病学进展.2007,28(5): 665.
[8]美国卫生研究院,美国心肺血研究院.美国高血压教育计划,美国联邦委员会关于高血压预防、检测、评定及治疗第六次报告[J].心血管病学进展.1998,19(4):242-244.
[9] Burnier M, Schneider MP , Chioléro A , et al. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions[J].J Hypertension.2001,19(6):335-341.
[10]沈洪兵,钮菊英,姚才良,等.饮茶与血压关系的流行病学调查[J].高血压杂志.1999,4(2): 156.
[11] Sleight P. Smoking and hypertension[J] . Clin Exp Hypertens. 1983 ,24(2):233.
[12] O’Rorke JE, Richardson W S. What to do when blood pressure is difficult to control[J]. Br Med J. 2001, 322 (7296): 1229-1232.
[13] Garg J P, Elliott WJ ,Folker A, et al. Resistant hypertension revisited: A comparison of two university-based cohorts[J]. Am J Hypertension. 2005,18(6):619-626.
[14] Whelton A, Fort J G, Puma JA, et al. Cyclooxygenase - 2$ specific inhibitors andcardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients[J]. Am J Ther. 2001,8:85-95.
[15] Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic[J]. Arch Intern Med. 1991,15(6): 1786-1792.
[16]纪宝华.顽固性高血压治疗对策[J].中华心血管病杂志,2003,31(5):396.
[17] Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts[J].Am J Hypertens. 2005,18(5,pt1):619-626.
[18]纪宝华.顽固性高血压应警惕原发性醛固酮增多症[J].高血压杂志.2002,10(4):306.
[19] Calhoun DA, N ishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subject swith resistant hypertension[J]. Hypertension. 2002, 40(6):892-896.
[20] Shopard JP. Cardiorespiratory changes on obstructive sleep apnea. In:Kergger. Roth, Dement: principles and practice of sleep medicinend [J].Philadelphia.
[21] 1994,86(5): 657-666.
[22]李岩.继发性高血压的诊断[J]..实用乡村医生杂志.2003,10(6):34-36.
[23] Park J, Campese V. Clinical characteristics of resistant hypertension: the importance of comp liance and the role of diagnostic evaluation in delineating pathogenesis[J]. J Clin Hypertens. 2007, 9 (supp l 1) : 7212.
[24] MoserM, Setaro JF. Resistant or difficult to control hypertension [J]. N Engl J Med. 2006, 355(4): 385-392.
[25] Hirsch S. A different approach to resistant hypertension [J]. Cleveland Clin J Med.
[26] 2007, 74(6): 449-456.
[27] Nishzaka MK, Zaman MA, Calhoun DA. Efficacy of low-dosesp ironolactone in subjectswith resistant hypertension[J]. Am J Hypertens. 2003, 16 (11, pt1):925-930.
[28] Zannad F. Aldosterone antagonist in resistant hypertension [J]. J Hypertens. 2007, 25(4):747-750.
[29] Epstein M. Resistant hypertension: prevalence and evolving concepts [J]. J Clin Hypertens. 2007, 9 (supp l 1):226.